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INTRODUCTION
The obstructive sleep apnea syndrome (OSAS) is characterized
by periods of breathing cessation and reduced breathing. Many
studies have suggested that OSAS elevates the risk for cardio-
vascular morbidities such as systemic hypertension, coronary
heart disease, atherosclerosis and stroke independently of other
known risk factors (1-5). The presence of repetitive nocturnal
hypoxemia, negative intrathoracic pressure and arousal states in
OSAS patients are associated with the activation of sympathet-
ic, hormonal, thrombotic, and metabolic factors (6). Although
the precise mechanisms have not yet been elucidated, one pos-
sible etiology may include the pathophysiology of endothelial
dysfunction (6). In addition, inflammatory processes may be asso-
ciated with OSAS which may act as potential mediators of car-
diovascular morbidities in these patients (4). 
There are variable biomarkers such as white blood cell count,
serum interleukin-6, fibrinogen, C-reactive protein (CRP), albu-
min concentration and erythrocyte sedimentation rate (ESR) that
are indices of systemic inflammation (7). Recent interest has been
focused on the association between circulating inflammatory bio-
markers and the severity of OSAS as well as the prediction of
cardiovascular events in patients with OSAS (8). Furthermore,
patients with OSAS and elevated plasma CRP levels have shown
a reduction in their levels of CRP after treatment with nasal con-
tinuous positive airway pressure (9). 
The ESR, which measures the tendency of red blood cells to
aggregate, is a widely used laboratory test. ESR has been report-
ed to be elevated in many of the acute and chronic diseases char-
acterized by tissue necrosis and inflammation (10). The normal
range of ESR is 0-10 mm/hr for men and 0-15 mm/hr for women.
Objectives. The erythrocyte sedimentation rate (ESR) is a marker for inflammation, and it has been identified as a risk
factor for atherothrombotic cardiovascular disease. The aim of this study was to determine the relationship between
the plasma ESR level and nocturnal oxygen desaturation or other polysomnographic variables and to examine the
role of obesity in patients with obstructive sleep apnea syndrome (OSAS).
Methods. This retrospective study included 72 patients with a diagnosis of OSAS who underwent overnight polysomnog-
raphy and routine blood tests between July and December of 2005. We compared the plasma ESR level with the
sum of all the polysomnographic variables and divided the patient group into obese and non-obese patients.
Results. The mean ESR level was 8.45 mm/hr. There was a significant difference in the ESR level between genders
(P<0.001). A significant correlation was found between the percentage of time spent at a SpO2 below 90% and
the ESR level in the obese group (BMI ≥25, N=43, P=0.012). In addition, the ESR levels had a positive correla-
tion with age in the obese group (P=0.002). However, there was no significant correlation with the percentage of
time spent at a SpO2 below 90% in the whole group of patients and in the non-obese group (BMI <25, N=29). The
ESR level showed no correlation with the other polysomnographic variables.
Conclusion. The duration of deoxygenation in obese patients with OSAS may be associated with the ESR level which is
an independent predictor of cardiovascular disease.
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Original ArticleHowever, the upper limit of the normal range increases with ad-
vancing age and obesity (7). A recent study has reported that after
adjusting for gender and hematocrit, ESR was directly associated
with coronary atherosclerosis (7). Although ESR is a cheap and
widely used test and has a possible predictive value for cardio-
vascular disease (11), there have been few reports on the relation-
ship between the plasma ESR level and the severity of hypox-
emia or the risk for cardiovascular events in OSAS patients.
The aim of this study was to determine the relationship be-
tween the plasma ESR level and the demographic data or pol-
ysomnographic variables of OSAS patients and to examine the
role of obesity in OSAS patients. In particular, we evaluated the
relationship between the duration of nocturnal oxygen desatu-
ration and the plasma ESR level in the study group and analyzed
the results in obese and non-obese patients. 
MATERIALS AND METHODS
Seventy-two patients (age range, 24 to 67 yr; mean age, 45.2
yr) who were diagnosed with OSAS by polysomnography and
referred to the Department of Otorhinolaryngology between
July and December of 2005 were enrolled in this study. Patients
who had a medical history of cardiovascular disease (cardiac
failure, angina pectoris, myocardial infarction, or stroke), inflam-
matory diseases (chronic sinusitis or chronic renal failure), trans-
plantation or other surgery and a previous history of therapy
using continuous positive airway pressure (CPAP) were exclud-
ed from the study.
The study was approved by the Institutional Ethics Committee
at our hospital, and informed consent was obtained from all pa-
tients. Information on smoking habits, alcohol consumption, the
use of antihypertensive drugs, and a history of diabetes was ob-
tained from a self-administrated questionnaire. In addition, all
patients received the Epworth Sleepiness Scale (ESS) test which
evaluates subjective daytime somnolence. Blood samples were
collected to measure the plasma ESR level (mm/hr) using the
Test1 kit (ALIFAX SPA, Padova, Italy). The body mass index
(BMI) was calculated, and patients were categorized into obese
(BMI ≥25) and non-obese (BMI <25) groups. All patients re-
ceived overnight polysomnography in order to evaluate the objec-
tive somnolence. Polysomnography was performed using an
Alice3 (Healthdyne Technologies
�, Marietta, GA, USA) recorder.
Electroencephalogram (C3-A2 and C4-A1), left and right elec-
tro-oculograms, electrocardiogram, chin and anterior tibialis
electromyograms, abdominal and thoracic movements by induc-
tive plethysmography, nasal/oral airflow, and oxygen saturation
by pulse oxymetry (SpO2) were monitored during the test. Apnea
was defined as the cessation of breathing for at least 10 sec, and
hypopnea was defined as a decrease in airflow of at least 50%
or a decrease in SpO2 of at least 4%, compared to the baseline.
The apnea-hypopnea index (AHI), apnea index (AI), lowest sat-
uration, and the percentage of time spent at a SpO2 below 90%
(sleep time at SpO2 below 90%/total sleep time ×100) were
obtained.
Statistical analyses were performed using SPSS ver. 11.5 (SPSS
Inc., Chicago, IL, USA). The Student t test was used to deter-
mine the relationship between the plasma ESR level and the
demographic data, such as gender, or a history of smoking, alco-
hol, diabetes mellitus, and hypertension. Simple and multiple
linear regression analyses were used to statistically determine the
relationship between the plasma ESR level and the other poly-
somnographic variables. The parameters included age, BMI, AHI,
AI, lowest saturation, and the percentage of the time spent at a
SpO2 below 90%. The significance level was set at P<0.05 in
all analyses.
RESULTS
The clinical characteristics of the study population are summa-
rized in Table 1. The mean ESR level was 8.45±7.00 for all
patients. The plasma ESR level was significantly higher in female
patients than in male patients (median, 14.22 ver. 7.54; P=0.007).
For all patients, there was no significant correlation between the
plasma ESR level and the polysomnographic variables or the
demographic data except for gender (Tables 2, 3). However in
the obese group, there was a significant correlation between the
plasma ESR levels and the percentage of time spent at a SpO2
below 90% (BMI ≥25, n=43, P=0.012; correlation coefficient,
R
2=0.148, β =0.387; 95% confidence interval, 0.036-0.276) (Fig.
1). The mean ESR level was 8.00±6.96, and the mean percent-
age of time spent at a SpO2 below 90% was 11.47±16.92% in
the obese group. Other polysomnographic variables such as AHI,
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Variables
Total Obese Non-obese
patients patients patients
Table 1. Clinical characteristics and polysomnographic data of the
study population
Values are expressed as mean±standard deviation.
BMI: body mass index; ESR: erythrocyte sedimentation rate; PSG: polyso-
mnography; AHI: apnea-hypopnea index; AI: arousal index; ESS: Epworth
sleep scale.
No. of subjects 72 43 29
Mean age  45.15±9.89 45.70±9.48 44.34±10.59
(range, yr) (24.0-67.0) (30.0-64.0) (23.0-67.0)
M:F 63:9 38:5 25:4
Mean BMI (kg/m
2) 25.62±2.34 27.02±1.74 23.55±1.36
Mean level of ESR (mm/hr) 8.45±7.00 8.00±6.96 9.20±7.15
History
Smoker:Nonsmoker 29:40 17:25 12:15
Alcoholic:Nonalcoholic 42:27 24:18 18:9
Hypertension (no.) 7 4 3
Diabetes mellitus (no.) 3 3 0AI, and the lowest O2 saturation revealed no significant correla-
tion with the plasma ESR levels. In addition, the mean age of
the obese group was 45.70±9.48 yr which was positively cor-
related with the plasma ESR level (P=0.002; R
2=0.205, correla-
tion coefficient, β =0.477; 95% confidence interval, 0.150-0.577)
(Fig. 2). To investigate the independent factors associated with
increased ESR levels, we performed a multivariate analysis for
age, gender, and all other studied variables. In our multivariate
analysis, the plasma ESR level was associated only with the per-
centage of time spent at a SpO2 below 90% (P=0.007; correla-
tion coefficient, β =0.369; 95% confidence interval, 0.043-0.254)
and age (P=0.001; correlation coefficient, β =0.463; 95%
confidence interval, 0.153-0.552) in the obese group. In the non-
obese group, there was no significant correlation between the
plasma ESR level and the demographic data or the polysomno-
graphic variables.
DISCUSSION
Silvestrini et al. (12) first demonstrated that male patients with
severe OSAS have an increased risk for carotid atherosclerosis
independent of any other concurrent, confirmed, vascular risk
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A. Total patients, N=72 (mean level of ESR: 8.45±7.00 mm/hr)
Table 3. Polysomnography data and ESR levels of OSAS patients
*The percentage of the length of time spent at SpO2 below 90%
ESR: erythrocyte sedimentation rate; OSAS: the obstructive sleep apnea
syndrome; BMI: body mass index; AHI: apnea-hypopnea index; AI: arousal
index; ESS: epworth sleep scale; SpO2: oxygen saturation by pulse oxym-
etry.
Variables
Mean±standard β P-value
deviation
Age (range, yr) 45.15±9.89 0.170 0.166
BMI (kg/m
2) 25.62±2.34 0.031 0.802
AHI (/hr) 45.98±23.59 0.092 0.457
AI (/hr) 49.23±20.08 0.141 0.252
ESS 11.35±3.93 -0.066 0.743
T% SpO2 <90 (%)* 9.85±14.90 0.221 0.073
Lowest O2 (%) 77.33±8.42 -0.088 0.478
B. Patients with BMI ≥25, N=43 (mean level of ESR: 8.00±6.96 mm/hr)
Variables
Mean±standard β P-value
deviation
Age (range, yr) 45.70±9.48 0.477 0.002
AHI (/hr) 48.57±23.67 0.135 0.399
AI (/hr) 50.18±21.98 0.058 0.719
ESS 11.73±4.13 -0.176 0.530
T% SpO2 <90 (%)* 11.47±16.92 0.387 0.012
Lowest O2 (%) 76.61±8.52 -0.283 0.073
C. Patients with BMI <25, N=29 (mean level of ESR: 9.20±7.15 mm/hr)
Variables
Mean±standard β P-value
deviation
Age (range, yr) 44.34±10.59 -0.224 0.282
AHI (/hr) 42.16±23.34 0.021 0.922
AI (/hr) 47.81±18.95 0.284 0.169
ESS 10.82±3.76 -0.034 0.926
T% SpO2 <90 (%)* 7.45±11.11 -0.121 0.564
Lowest O2 (%) 78.42±8.40 0.059 0.780
Fig. 1. Relationship between the plasma ESR level and age in the
obese group (BMI ≥25, N=43). There was a significant correlation
between the plasma ESR level and age in the obese group (P=0.002;
R
2=0.205, correlation coefficient, β =0.477; 95% confidence interval,
0.150-0.577).
ESR: erythrocyte sedimentation rate. 
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A. Total patients, N=72
Table 2. Demographic data and ESR levels of OSAS patients
Values are expressed as mean±standard deviation.
ESR: erythrocyte sedimentation rate; OSAS: obstructive sleep apnea syn-
drome.
Variables ESR level (mm/hr) P-value
Sex (M:F) 7.54±6.47:14.22±7.87 0.007
Smoking (smoker:nonsmoker) 7.56±5.60:9.46±7.87 0.263
Hypertension (yes:no) 14.11±10.52:7.52±5.80 0.100
Diabetes mellitus (yes:no) 14.30±12.00:8.10±6.70 0.340
B. Patients with BMI ≥25, N=43
Variables ESR level (mm/hr) P-value
Sex (M:F) 7.11±6.17:14.40±9.66 0.002
Smoking (smoker:nonsmoker) 7.94±6.10:8.30±7.71 0.869
Hypertension (yes:no) 5.25±4.57:8.19±6.45 0.319
Diabetes mellitus (yes:no) 14.30±12.00:7.50±6.40 0.102
C. Patients with BMI <25, N=29
Variables ESR level (mm/hr) P-value
Sex (M:F) 8.29±7.05:14.00±6.38 0.174
Smoking (smoker:nonsmoker) 6.90±4.89:11.36±8.04 0.107
Hypertension (yes:no) 22.51±12.02:7.89±5.32 0.762factors. There is increasing evidence for the existence of a causal
relationship between OSAS and cerebrovascular disease (6, 13).
Many studies have documented that the functional outcome of
OSA patients is poorer if they had a recent stroke or transient
ischemic attack, and the mortality rate at 1-yr follow-up was high-
er than in stroke patients without OSAS (14-18). Although the
explanations for these findings are incomplete, it has been sug-
gested that a combination of sleep deprivation and hypoxemia
may aggravate the disease process. In addition, a recent poly-
somnographic study reported that patients with the OSAS have
more severe plaque formation than patients who do not have
OSAS (19).
A recent hospital-based study with a large population of pa-
tients showed that inflammatory markers such as CRP, WBC
count and fibrinogen tend to correlate with obesity, central dis-
tribution of body fat, higher blood pressure, hyperglycemia,
lower HDL-cholesterol, and hyperinsulinemia which are all risk
factors for cardiovascular disease such as atherosclerosis (20). In
addition, CRP has been suggested to be a risk factor for a myocar-
dial infarction (21). To date, a few prospective population-based
studies have shown the long-term predictive value of ESR in rela-
tion to the development of cardiovascular disease (10). The Sto-
ckholm Prospective Study Group demonstrated that ESR was an
independent risk factor for myocardial infarction (22); in addi-
tion, another study suggested that ESR predicts events associat-
ed with the development of ischemic heart disease (23).
A correlation between inflammatory markers, especially CRP,
and the severity of OSAS has been reported. Shamsuzzaman et
al. (6) found that in 22 newly diagnosed patients with OSAS,
there was a significant increase in CRP levels compared with 20
normal subjects, and they concluded that the magnitude of the
CRP elevation was significantly associated to the severity of
OSAS. However, there have been few reports on the correlation
between the severity of OSAS and plasma ESR levels which is
an important inflammatory marker. ESR, which is an indicator
of red cell aggregation and thus blood viscosity, is a routine lab-
oratory test widely used to screen for the presence of inflamma-
tion and for the initial diagnosis and follow-up of chronic diseases
(7). Physiologically, ESR relates to both the underlying blood
rheology and the inflammatory responses (24). A few studies
have proposed that ESR is an independent predictor of coronary
heart disease (24).
We found a positive correlation between the plasma ESR level
and the severity of OSAS which was assessed by the percentage
of time spent at a SpO2 below 90% in obese patients, indepen-
dent of the smoking status, alcohol consumption and the presence
of hypertension or diabetes mellitus. Since there is a tendency
for the plasma ESR level to increase with adiposity, we divided
the patients into obese and non-obese groups to eliminate this
confounding factor. There were no positive correlations with ESR
in the non-obese group. 
In this study, we evaluated the correlation between the percent-
age of the time spent at a SpO2 below 90% and the plasma ESR
level by pulse oxymetry. The advantage of pulse oxymetry is that
it reflects only significant desaturation which is an objective test,
whereas there is a large variation in other polysomnographic
measurements such as AHI between readers. Based on the results
that there is a significant correlation between the ESR level and
the time spent at a SpO2 below 90% and whereas there was no
significant correlation between the ESR level and other polyso-
mnographic variables, it is conceivable that the desaturation time
may be related to the risk for cardiovascular disease. In addition,
Nieto et al. (25) reported that after controlling for the main
potential confounders, high levels of AHI or time at sleep with
below 90% oxygen saturation was associated to greater odds
ratios for hypertension. Furthermore, Hoffstein et al found sig-
nificantly increased hematocrit levels when contrasting patients
in the lowest and highest quartiles for percent of total sleep time
spent at oxygen saturation <85% (26). Moreover, our multivari-
ate analysis showed that the ESR levels were higher in women
compared to men and increased with advancing age. Recent stud-
ies have shown that gender may affect the upper limit of the nor-
mal ESR level and that the ESR level is slightly higher in women
(0-15 mm/hr) than in men (0-10 mm/hr) (7).
One limitation of this study is its small sample size and lack of
female subjects. Thus, further studies with a larger sample size
of female subjects are needed to confirm the correlation between
the ESR levels and the female gender. The results of this study
suggest that there may be a positive association between the plas-
ma ESR level and nocturnal oxygen desaturation in obese patients.
The duration of deoxygenation in OSAS patients may be asso-
ciated with the ESR level which is an independent predictor of
cardiovascular disease.
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Fig. 2. Relationship between the plasma ESR level and the percent-
age of time spent at a SpO2 below 90% in the obese group (BMI ≥
25, N=43). In the obese group, the plasma ESR level was positively
correlated with the percentage of time spent at a SpO2 below 90%
(P=0.012; R
2=0.148, correlation coefficient, β =0.387; 95% confi-
dence interval, 0.036-0.276).
ESR: erythrocyte sedimentation rate; SpO2: oxygen saturation by pulse
oxymetry. 
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